

Press information

Rodos Biotarget will host 'Future Medicine Symposium'

The biopharmaceutical company Rodos Biotarget GmbH will hold its 'Future Medicine Symposium' on Friday, 4 November 2016.

Hannover, Germany, 28 October 2016. A biopharmaceutical company, Rodos Biotarget joins the ranks of industry leadership in targeted drug delivery. Based on its proprietary TargoSphere[®] technology, the enterprise provides tailor-made nanocarriers to enable improved therapeutic and prophylactic approaches for diseases of high medical need.

Rodos' symposium will take place at the 'Forum Niedersachsen' in Hannover, Germany. The company's management has invited top-notch speakers who will present novel therapeutic modalities on established drugs, proteins and peptides, and gene therapeutics. According to the event's title, 'With TargoSpheres[®] Towards New Therapies', these life science experts will pay particular attention to how these drug classes – and certainly the patients – will benefit from TargoSphere[®]-enabled applications against infectious diseases, liver disorders, cancers, and other indications.

The event is primarily aimed at a broad range of interested people and supporters in order to develop and provide Rodos Biotarget's promising new treatment options as quickly as possible.

Future Medicine Symposium: With TargoSpheres[®] Towards New Therapies

Friday, 4 November 2016

'Forum Niedersachsen', Feodor-Lynen-Str. 27, 30625 Hannover, Germany

2:00 pm: Begin of the Exclusive Future Medicine Symposium (Part 1). Dr. Marcus Furch (CEO and Managing Director / Rodos Biotarget GmbH)

Welcome and Introduction

2:15 pm: Gene Therapies

Prof. Dr. Michael Ott (Clinical Research Unit 'Cell and Gene Therapy', TWINCORE, Hannover)

Gene-therapeutic Approaches: Chances, Obstacles – and Reasons for Overcoming such Obstacles with TargoSpheres[®]

2:45 pm: Bacterial Infectious Diseases: Antibiotics 'in a New Guise'

Prof. Dr. Ulrich Kalinke (Institute for Experimental Infection Research, TWINCORE, Hannover)

Tuberculosis: Options for Fighting Multiresistant Strains with the Aid of TargoSpheres[®]

3:15 pm: Immuno-Oncologic Approaches

Prof. Dr. J. Hinrich Peters (Faculty of Medicine, Georg August University, Göttingen)

Dendritic Cells: Powerful Allies in the Fight Against Cancer, and the Potential of TargoSphere[®]-mediated Cancer Therapies

3:45 pm: Cancer of the Liver

Prof. Dr. Ali Canbay (Dept. of Gastroenterology and Hepatology, University of Essen Medical School, Essen)

Pinpointing Hepatocellular Carcinoma with TargoSpheres[®] – and the Essential Role of a New Ex-Vivo Liver Perfusion System

4:15 pm to 4:45 pm: Interactive Panel Discussion

All speakers and the Managing Directors of Rodos Biotarget GmbH

Future Medicine: Opportunities of Targeted Drug Delivery for Future Therapies

Break

Begin of public event. Please note that registration is required at: crowd@biotargeting.de

5:15 pm: Dr. Robert Gieseler (CSO and Managing Director / Rodos Biotarget GmbH)

Welcome and Wrap-up of Part 1

5:30 pm: Short Welcoming Speech by Ms. Silke Jester (BioRegioN / Innovation Center of the Lower Saxony Ministry of Economic Affairs, Labor and Transport, Hannover)

The Significance of the Life Sciences – and an Outlook on the German Biotechnology Days 2017 in Hannover

5:45 pm: Dr. Marcus Furch (CEO and Managing Director / Rodos Biotarget GmbH)

Rodos Biotarget: What are the Chances for an investment?

We will discuss with you and will respond to your questions.

Afterwards: Networking with catering.

About Biotarget GmbH

Rodos Biotarget GmbH is a biopharmaceutical company that joins the ranks of industry leadership in nanocarriers for drug delivery. Rodos has developed the versatile TargoSphere[®] platform technology comprising biocompatible and biodegradable nanocarriers. These are designed to achieve enhanced prophylactic and therapeutic approaches against diseases of high and unmet medical need like cancers, chronic infections, autoimmune diseases, and neurological diseases. Rodos Biotarget offers TargoSphere[®] to the pharmaceutical industry as a “construction kit”: Specific additives and components of the nanocarriers can be tailored to suit the respective medical objective. The spherical body can be tuned to prolong blood circulation and/or sustained release of the drug payload. Targeting ligands located on the nanocarrier’s surface permit specific delivery of the drug within close proximity to target cells and/or allow for the selective uptake of encapsulated actives into such cells. Rodos nanocarriers aim to improve a drug’s pharmacokinetics, pharmacodynamics, and safety profile, and they also allow for line and label extensions. Rodos pushes the commercialization of its patented technology platform with two in-house therapeutic applications: TargoBiotics[™] for the treatment of intracellular bacterial infections, and TargoVir[™] for the treatment of devastating viral diseases.

Additional Information: <http://www.biotargeting.eu>

Contact Rodos Biotarget GmbH:

Rodos Biotarget GmbH
Medical Park Hannover
Feodor-Lynen-Str. 31
D-30625 Hannover / FRG
Tel.: +49 (511) 7273 8835
Fax: +49 (511) 214 7076
m.furch@biotargeting.eu